Hansoh Pharma Licenses Hengrui’s Late-Stage Kidney Drug SHR6508 for China
I'm PortAI, I can summarize articles.
Hansoh Pharmaceutical Group has signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals for SHR6508, a kidney drug in Phase III trials, for mainland China. The deal includes an upfront payment of RMB30 million, potential milestone payments up to RMB190 million, and tiered royalties. This complements Hansoh's nephrology portfolio, enhancing execution efficiency without affecting Hong Kong listing rules. Analysts rate Hansoh stock as a Buy with a HK$48.20 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments